Celularity Inc. Class A Common Stock (CELU) is a publicly traded Healthcare sector company. As of May 21, 2026, CELU trades at $0.83 with a market cap of $23.11M and a P/E ratio of -0.31. CELU moved +4.21% today. Year to date, CELU is -34.51%; over the trailing twelve months it is -64.58%. Its 52-week range spans $0.71 to $5.22. Rallies surfaces CELU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Celularity Regains Nasdaq Compliance, Cuts $13M Liabilities After 2025 10-K: Celularity filed its 2025 Form 10-K on April 30, 2026, and on May 1 regained compliance with Nasdaq Listing Rule 5250(c)(1). The company out-licensed its biomaterials portfolio, cut liabilities by about $13 million and realigned personnel to focus on its core longevity and cell therapy platforms.
| Metric | Value |
|---|---|
| Price | $0.83 |
| Market Cap | $23.11M |
| P/E Ratio | -0.31 |
| EPS | $-2.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.22 |
| 52-Week Low | $0.71 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $54.22M |
| Net Income | $-57.89M |
| Gross Margin | 72.36% |
CELU analyst coverage data. Average price target: $0.00.